You are here

Health Care & Law

Digital health products are coming on strong, and P&T committees and health care professionals will have to manage their use.

Timothy Aungst PharmD
F. Randy Vogenberg PhD, RPh
As marijuana legalization and use expands across the U.S., health care systems are struggling to keep abreast of the changes and trends in regulations. Considering marijuana’s federal illegality and other restrictions on its use, the limited evidence for its clinical efficacy, and the myriad psychological adverse events, caution is recommended when establishing policies and procedures regarding coverage of marijuana and CBD products.
James O’Donnell PharmD, MS, FCP
F. Randy Vogenberg BSc Pharm, PhD
Increased cannabis use has brought about a sea change in policy and attitudes toward regulation, and a multitude of rules that vary widely between states. The disparity has stymied any effective response to the problems surrounding access to cannabis products for those in need. Health care providers and practitioners, as well as P&T committees, must carefully undertake decisions on rational drug use, whether or not their patients are using cannabis while under their care.
Rita Marcoux RPh, MBA
Lauren Holmes PharmD, MBA, MPH
F. Randy Vogenberg RPh, PhD
In the complex setting of obstetrics and reproductive medicine, the medication-related injuries leading to the most litigation involve some of the most commonly used drugs, rather than the newer, more complicated therapies. The authors present a number of cases illustrating how sophisticated treatment of high-risk pregnancies can be jeopardized by a simple negligent act.
James T. O’Donnell PharmD, MS, FCP
James J. O’Donnell PhD
F. Randy Vogenberg BSc Pharm, PhD

The authors underscore the importance of understanding standards and procedures as they discuss two lawsuits that arose from drug injury.

James T. O’Donnell PharmD, MS, FCP
F. Randy Vogenberg BSc Pharm, PhD

Despite a slow legislative start by President Trump, new federal and state regulatory health care changes will have important implications for pharmacists, P&T committees, and patients.

F. Randy Vogenberg BSc, PhD, RPh
Rita Marcoux BSc, MBA, RPh

Telehealth is becoming mainstream in the U.S., as more consumers, employers, hospital systems, and even insurers adopt the technology. The authors explore the challenges of regulation, reimbursement, and licensing as the modality evolves.

Rita M. Marcoux RPh, MBA
F. Randy Vogenberg RPh, PhD

Involving pharmacists in the process of comparing the medications that should be ordered for a patient with the new medications that are currently ordered and resolving differences improves accuracy, decreases mortality, and improves transitions of care.

Jennifer Splawski PharmD, BCPS
Heather Minger PharmD, BCPS

Although the health care marketplace is changing rapidly, some things have not changed, including the need for P&T committees and organizations’ management to beware of ethical and legal issues such as discrimination, quotas, and understaffing.

James O’Donnell PharmD
F. Randy Vogenberg RPh, PhD
Part 2: Risk Management Recommendations

A malpractice claims analysis by an insurer, Healthcare Providers Service Organization, provides recommendations for avoiding errors and injuries. Case examples relate these suggestions to situations that are common in health care settings.

James O’Donnell PharmD
F. Randy Vogenberg RPh, PhD